Chad McAuliffe
プリンシパル
Expertise:
Chad provides high-impact results for biopharmaceutical companies through strategy and pricing initiatives. His experience includes revenue-optimal pricing for rare disease therapies, market assessments informing product launch decisions and product commercialization, and payer insight research for innovative therapeutics.
Before joining EVERSANA, Chad worked on international engagements across a wide range of therapeutic areas at Simon-Kucher & Partners. His focus there also spanned commercial diagnostic strategy, global resource development, and value-based contract testing. Prior to his role at Simon-Kucher, Chad was a Business Intake Paralegal at Keefe Disability Law, where he grew familiar with Centers for Medicare and Medicaid Services programs and helped to grow the firm’s client base through direct customer outreach.
Chad earned a Bachelor of Arts degree in English literature from Brown University and was in the University Honors Program.
Articles by Chad McAuliffe
Proactive Steps to Ensure Appropriate Utilization of the First Disease-Modifying Therapy for Alzheimer Disease
Widespread hope exists that aducanumab will soon gain Food and Drug Administration approval as the first disease-modifying therapy for patients with mild cognitive impairment associated with Alzheimer disease (AD), which could significantly impact the management of AD. If approved, challenges need to be addressed to properly identify patients who will benefit from treatment and ensure access. EVERSANA experts provide recommendations for proactive steps for key stakeholders – patients, providers, health systems, CMS services, and payers – on where pathways can help to ensure that all aspects of the Quadruple Aim—individual patient experience, population health, cost of care, and caregiver support—are addressed. Attainment of each of these aims is only possible […]